Welcome to our dedicated page for Synaptogenix news (Ticker: SNPX), a resource for investors and traders seeking the latest updates and insights on Synaptogenix stock.
Synaptogenix, Inc. (NASDAQ: SNPX) is an emerging clinical-stage biopharmaceutical company focused on the development of innovative therapies for neurodegenerative diseases. The company leverages its lead drug candidate, Bryostatin-1, in addressing various challenging conditions such as Alzheimer's disease, Fragile X syndrome, multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and traumatic brain injury.
Synaptogenix is currently conducting clinical and preclinical trials to evaluate the efficacy and safety of Bryostatin-1. This drug, which activates protein kinase C (PKC), has shown potential in promoting synaptic growth, reducing inflammation, and aiding cognitive function. Recent achievements include partnering with the Cleveland Clinic for a Phase 1 trial of Bryostatin-1 aimed at cognitive impairment in MS and discovering potential benefits in treating ALS.
The company has also gained significant attention from the research community, with notable publications in esteemed journals like the Journal of Alzheimer's Disease and involvement in high-profile scientific forums. Leveraging its substantial financial resources, Synaptogenix continues to explore additional therapeutic avenues and partnerships, including a significant stake in Cannasoul Analytics, aiming to develop cannabinoid-based treatments.
Synaptogenix’s financial health is stable, bolstered by approximately $35.8 million as of March 31, 2023, and $33 million as of June 30, 2023, ensuring continuous development of its drug candidates. The company's recent reverse stock split aligns with strategic efforts to maintain NASDAQ compliance and increase stock value.
Synaptogenix, Inc. (Nasdaq: SNPX) praised Biogen's FDA approval of Aducanumab for Alzheimer's treatment, emphasizing its commitment to innovative therapies for the disease. While acknowledging Biogen's efforts, Synaptogenix focuses on a restorative approach through its lead compound, Bryostatin-1, currently in an extended clinical trial. Bryostatin-1 is designed to regenerate brain synaptic networks and reduce amyloid levels. The company has previously conducted substantial studies on Bryostatin-1, establishing a robust safety database. The FDA has granted it Orphan Drug Designation for Fragile X syndrome.
Synaptogenix, Inc. (OTC: SNPX) has received approval to uplist to The Nasdaq Capital Market, effective June 7, 2021. This uplisting marks a significant milestone for the biopharmaceutical company, which focuses on treatments for neurodegenerative diseases. CEO Alan Tuchman and President Daniel Alkon emphasized that this transition will enhance visibility and outreach to investors. The company's lead therapeutic candidate, Bryostatin-1, has shown promise in clinical studies for conditions like Alzheimer's and Fragile X syndrome. The FDA has granted Orphan Drug Designation to Bryostatin-1 for Fragile X.
Synaptogenix, Inc. (OTC: SNPX) has approved a one-for-four reverse stock split to meet Nasdaq listing requirements, effective May 19, 2021. This decision aims to enhance the company’s visibility and liquidity in the market. Post-split, approximately 3,508,129 shares will remain outstanding. Although the company is optimistic about the uplisting, it cautions that there are no guarantees of meeting Nasdaq's criteria. The initiative is part of Synaptogenix's broader strategy to advance its lead candidate, Bryostatin-1, for treating neurodegenerative diseases.
Synaptogenix, Inc. (OTC: SNPX) announced that Dr. Daniel Alkon will present a "Spotlight Showcase" titled "Regenerative Therapeutics" on April 28, 2021, at 12:40 PM ET. The showcase highlights Synaptogenix's work on therapies for neurodegenerative diseases, particularly focusing on Bryostatin-1, which may restore cognitive function by inducing new synaptic connections. Ongoing NIH-supported trials are underway, aiming to assess Bryostatin-1's efficacy in Alzheimer's disease and other disorders. The presentation will be available on demand for registered participants and via social media after the event.
Synaptogenix, Inc. (OTC: SNPX) has provided an update on its Phase 2b clinical trial of Bryostatin-1 for moderately severe Alzheimer's disease. The trial has dosed 43 out of 100 targeted patients across 17 sites, with no safety issues reported. The trial aims for two 11-week dosing cycles and seeks to replicate a previous improvement of 4.8 Severe Impairment points. The CEO noted that enrollment is on track despite potential COVID-19 impacts, emphasizing a structured trial duration to mitigate placebo effect risks.
Synaptogenix, Inc. (OTC: SNPX) announced its participation in the H.C. Wainwright Global Life Sciences Conference, scheduled virtually for March 9-10, 2021. The presentation will feature CEO Alan Tuchman M.D. and President Daniel Alkon M.D., available on-demand starting at 7 a.m. EST on March 9. Synaptogenix focuses on developing therapies for neurodegenerative diseases, with its lead candidate, Bryostatin-1, showing promise in treating Alzheimer's and other conditions. The company has received Orphan Drug Designation from the FDA for Bryostatin-1 for Fragile X syndrome.
Synaptogenix (OTC: SNPX), a biopharmaceutical firm, announced its participation in two scientific conferences. On February 25, Dr. Daniel Alkon will present a virtual poster at the Neurodegenerative Drug Development Summit. On March 14, he will discuss findings from a pilot Phase II trial regarding Bryostatin-1's effects on Alzheimer's patients at the AD/PD 2021 conference. The trial revealed a significant improvement in Severe Impairment Battery scores. CEO Alan Tuchman expressed enthusiasm for sharing updates on ongoing trials and the development of Bryostatin-1.
Synaptogenix, Inc. (OTC: SNPX) announced participation in two scientific conferences on February 25 and March 14, focusing on neurodegenerative diseases. Dr. Daniel Alkon will present virtually at the 9th Annual Neurodegenerative Drug Development Summit and share findings from a pilot Phase 2 trial of Bryostatin-1 for Alzheimer's disease. The trial showed a significant improvement in cognitive scores. CEO Alan Tuchman expressed excitement for future updates on their ongoing studies.
Synaptogenix, Inc. (OTC: SNPX) announced its participation in the Winter Wonderland Conference from February 16-19, 2021. Dr. Alan Tuchman, CEO, and Dr. Daniel Alkon, CSO, will present on February 17 at 11:30 am EDT and hold one-on-one meetings on February 18 and 19. The conference, featuring curated presentations, aims to connect emerging biopharmaceutical opportunities with institutional investors. Synaptogenix focuses on developing neuro-regenerative therapies, especially Bryostatin-1 for Alzheimer's and other rare diseases, with FDA Orphan Drug Designation for Fragile X syndrome.
Synaptogenix, Inc. (OTC: SNPX), a biopharmaceutical firm focused on neurodegenerative therapies, has applied to list its common shares on the Nasdaq Stock Market. While the company believes it meets all listing requirements, approval is not guaranteed. CEO Dr. Alan J. Tuchman highlighted that Synaptogenix is well funded for its Phase 2 clinical trial of Bryostatin-1, its lead candidate for Alzheimer's treatment. The drug has received Orphan Drug Designation for Fragile X syndrome and has been tested on over 1,500 individuals, providing a substantial safety database.
FAQ
What is the current stock price of Synaptogenix (SNPX)?
What is the market cap of Synaptogenix (SNPX)?
What is Synaptogenix, Inc. focused on?
What are the main conditions Synaptogenix targets with Bryostatin-1?
What recent collaboration has Synaptogenix entered into?
What financial resources does Synaptogenix have to fund its operations?
What recent study findings support the potential of Bryostatin-1?
What is the significance of Synaptogenix's partnership with Cannasoul Analytics?
How is Synaptogenix ensuring compliance with NASDAQ regulations?
What are the potential benefits of Bryostatin-1 in Alzheimer's disease?
Has Synaptogenix received any accolades or recognition in the scientific community?
What are the forward-looking statements and risks related to Synaptogenix?
